Bioxytran (BIXT) Net Income towards Common Stockholders (2010 - 2026)
Bioxytran (BIXT) posted Net Income towards Common Stockholders of -$2.1 million for Q1 2026, down 296.24% sequentially from -$522155.0 in Q4 2025, and down 52.85% YoY from -$4.4 million in Q1 2025.
Bioxytran (BIXT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Bioxytran has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$2.1 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 52.85% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 million (up 10.17% YoY) and the FY2025 annual result came in at -$2.1 million, up 10.8% from the prior year.
- Net Income towards Common Stockholders declined to -$2.1 million in Q1 2026 per BIXT's latest filing, from -$522155.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $35437.0 in Q2 2025 and troughed at -$2.1 million in Q1 2026.
- A 5-year average of -$808838.1 and a median of -$752138.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders tumbled 455.09% in 2023, then jumped 105.36% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$865932.0 in 2022, then sank by 35.02% to -$1.2 million in 2023, then jumped by 35.67% to -$752138.0 in 2024, then surged by 30.58% to -$522155.0 in 2025, then slumped by 296.24% to -$2.1 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.1 million, -$522155.0, and -$282726.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -619,929.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.07 Mn |
| Dec 31, 2025 | -522,155.00 |
| Sep 30, 2025 | -282,726.00 |
| Jun 30, 2025 | 35,437.00 |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -752,138.00 |
| Sep 30, 2024 | -392,374.00 |
| Jun 30, 2024 | -661,647.00 |
| Mar 31, 2024 | -573,846.00 |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -1.13 Mn |
| Jun 30, 2023 | -1.45 Mn |
| Mar 31, 2023 | -817,977.00 |
| Dec 31, 2022 | -865,932.00 |
| Sep 30, 2022 | -203,149.00 |
| Jun 30, 2022 | -634,040.00 |
| Mar 31, 2022 | -912,270.00 |
| Dec 31, 2021 | -1.04 Mn |
| Sep 30, 2021 | -475,152.00 |
| Jun 30, 2021 | -896,701.00 |